Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
S335814-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $87.90 | |
S335814-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $295.90 |
a potent, selective CB1 receptor antagonist
Synonyms | GTPL9234 | SR-01000946296 | JD 5001 | (S)-(-)-3-(4-chlorophenyl)-N'-(4-chlorophenylsulfonyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide | (S)-SLV 319 | (S,E)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-N-methyl-4-phenyl-4,5-dihydro-1 |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Cannabinoid CB1 receptor antagonist |
Product Description | (S)-SLV 319 is a potent and selective CB1 receptor antagonist (K|i|= 7.8) with much weaker effects on CB2 (K|i|= 7,943 nM). (S)-SLV 319 is more water soluble than other known CB1 receptor ligands due to its less lipophilic nature. |
ALogP | 5.3 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|---|---|---|---|---|---|---|
Cannabinoid CB1 receptor agonist | AGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | DailyMed: [1] | |
Cannabinoid CB1 receptor agonist | AGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | ||
Cannabinoid CB1 receptor agonist | AGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | ||
Cannabinoid CB1 receptor antagonist | ANTAGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | PubMed: [1] | |
Cannabinoid CB1 receptor antagonist | ANTAGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | Other: [1] | |
Cannabinoid CB1 receptor antagonist | ANTAGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | ||
Cannabinoid CB1 receptor antagonist | ANTAGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | PubMed: [1] | |
Cannabinoid CB1 receptor agonist | AGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | ||
Cannabinoid CB1 receptor antagonist | ANTAGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | PubMed: [1] | |
Cannabinoid CB1 receptor inverse agonist | INVERSE AGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | PubMed: [1] |
IUPAC Name | (4S)-5-(4-chlorophenyl)-N-(4-chlorophenyl)sulfonyl-N'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide |
---|---|
INCHI | InChI=1S/C23H20Cl2N4O2S/c1-26-23(28-32(30,31)20-13-11-19(25)12-14-20)29-15-21(16-5-3-2-4-6-16)22(27-29)17-7-9-18(24)10-8-17/h2-14,21H,15H2,1H3,(H,26,28)/t21-/m1/s1 |
InChi Key | AXJQVVLKUYCICH-OAQYLSRUSA-N |
Canonical SMILES | CN=C(NS(=O)(=O)C1=CC=C(C=C1)Cl)N2CC(C(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4 |
Isomeric SMILES | CN=C(NS(=O)(=O)C1=CC=C(C=C1)Cl)N2C[C@@H](C(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4 |
PubChem CID | 9826744 |
Molecular Weight | 487.4 |
Melt Point(°C) | 173-174° C |
---|
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation H335:May cause respiratory irritation |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P271:Use only outdoors or in a well-ventilated area. P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing. P403+P233:Store in a well-ventilated place. Keep container tightly closed. P362+P364:Take off contaminated clothing and wash it before reuse. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P337+P317:If eye irritation persists: Get medical help. P332+P317:If skin irritation occurs: Get medical help. P319:Get medical help if you feel unwell. |
1. Lange JH, Coolen HK, van Stuivenberg HH, Dijksman JA, Herremans AH, Ronken E, Keizer HG, Tipker K, McCreary AC, Veerman W et al.. (2004) Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.. J Med Chem, 47 (3): (627-43). [PMID:14736243] [10.1021/op500134e] |